TITLE:
Promoter Region Analysis of STAMP1/STEAP2 Gene-Silencing of STAMP1/STEAP2 Gene Triggers P53 Upregulation
AUTHORS:
Ceren Gönen
KEYWORDS:
LNCaP, STAMP1/STEAP2, P53, RT-PCR
JOURNAL NAME:
CellBio,
Vol.12 No.1,
March
27,
2023
ABSTRACT: Prostate cancer is the most commonly diagnosed
cancer and the second leading cause of cancer mortality
in men in the Western World. In the initial stages, prostate cancer is
dependent on androgens for growth which is the basis for androgen ablation therapy. The effects of androgens
are mediated by the Androgen Receptor (AR). Therefore, studies focus on the identification of AR-regulated genes that are also
highly expressed in the prostate. STAMP family
genes STAMP1/STEAP2 and STAMP2/STEAP4 have only expressed in androgen receptor-positive cells, the role of AR in STAMP family gene expression is an important question. STEAP (Six Transmembrane Epithelial
Antigen of Prostate) is the first characterized prostate of enriched six transmembrane gene, expressed in metastatic prostate cancer
samples, it is tempting to speculate that STAMP/STEAP family genes may
be involved in similar functions with a role
for both the normal biology and pathophysiology of the prostate. Using siRNA
technology in LNCaP cells expressing STAMP genes per se, an apoptosis panel
including pro-apoptotic and/or apoptotic molecules was assayed by RT-PCR, By this research project,
prostate-specific STAMP gene family and its regulatory effects on the
p53- and caspase-related pathways were characterized.